Close Menu

NEW YORK – Becton Dickinson reported today that its fiscal year 2020 first quarter revenues rose 2 percent year over year. However, the firm lowered its guidance for the year due to evolving regulatory strategies for upgrades to its Alaris pump system.

For the three months ended Dec. 31, the company posted revenues of $4.23 billion compared to $4.16 billion in the year-ago quarter, and beat Wall Street analysts' average estimate of $4.18 billion. On a currency-neutral basis, revenues grew 2.5 percent, the firm said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.

Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.

In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.